©The Author(s) 2025.
World J Gastrointest Surg. Dec 27, 2025; 17(12): 111359
Published online Dec 27, 2025. doi: 10.4240/wjgs.v17.i12.111359
Published online Dec 27, 2025. doi: 10.4240/wjgs.v17.i12.111359
Table 4 Safety assurance of the new treatment method, n (%)
| Safety indicator | Injection group (n = 30) | Medication group (n = 30) | P value |
| Adverse event rate (%) | 10 | 26.7 | < 0.05 |
| Specific adverse events | |||
| Mild local pain | 6 (20) | 0 (0) | < 0.05 |
| Slight injection site redness | 3 (10) | 0 (0) | < 0.05 |
| Gastrointestinal discomfort | 0 (0) | 9 (30) | < 0.05 |
| Constipation | 0 (0) | 5 (16.7) | < 0.05 |
| Dizziness | 0 (0) | 4 (13.3) | < 0.05 |
| Nausea | 0 (0) | 3 (10) | < 0.05 |
| Headache | 0 (0) | 2 (6.7) | < 0.05 |
| Fatigue | 0 (0) | 3 (10) | < 0.05 |
| Severe adverse events | 0 (0) | 0 (0) |
- Citation: Shang S, Liu Y, Bai QL, Zhang Z, Liu J, Qi F. Latent myofascial trigger point injection improves symptoms in functional gastrointestinal disorders. World J Gastrointest Surg 2025; 17(12): 111359
- URL: https://www.wjgnet.com/1948-9366/full/v17/i12/111359.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i12.111359